Kowalska, K.; Walczak, J.; Femlak, J.; Młynarska, E.; Franczyk, B.; Rysz, J.
Empagliflozin—A New Chance for Patients with Chronic Heart Failure. Pharmaceuticals 2022, 15, 47.
https://doi.org/10.3390/ph15010047
AMA Style
Kowalska K, Walczak J, Femlak J, Młynarska E, Franczyk B, Rysz J.
Empagliflozin—A New Chance for Patients with Chronic Heart Failure. Pharmaceuticals. 2022; 15(1):47.
https://doi.org/10.3390/ph15010047
Chicago/Turabian Style
Kowalska, Klaudia, Justyna Walczak, Joanna Femlak, Ewelina Młynarska, Beata Franczyk, and Jacek Rysz.
2022. "Empagliflozin—A New Chance for Patients with Chronic Heart Failure" Pharmaceuticals 15, no. 1: 47.
https://doi.org/10.3390/ph15010047
APA Style
Kowalska, K., Walczak, J., Femlak, J., Młynarska, E., Franczyk, B., & Rysz, J.
(2022). Empagliflozin—A New Chance for Patients with Chronic Heart Failure. Pharmaceuticals, 15(1), 47.
https://doi.org/10.3390/ph15010047